GlobeNewswire: Poseida Therapeutics, Inc. Contains the last 10 of 41 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:04:57ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/05/13/1822448/0/en/Poseida-Therapeutics-Receives-US-FDA-Orphan-Drug-Designation-for-P-BCMA-101-for-the-Treatment-of-Multiple-Myeloma.html?f=22&fvtc=4&fvtv=26810Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma2019-05-13T12:00:00Z<![CDATA[SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to P-BCMA-101 for the treatment of relapsed and/or refractory multiple myeloma. P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac® platform technology. P-BCMA-101 is comprised of a high percentage of long-lived, self-renewing stem cell memory T cells targeting cancer cells expressing B-cell maturation antigen (BCMA).]]>https://www.globenewswire.com/news-release/2019/04/22/1807227/0/en/Poseida-Therapeutics-Raises-142-Million-in-Series-C-Financing.html?f=22&fvtc=4&fvtv=26810Poseida Therapeutics Raises $142 Million in Series C Financing2019-04-22T11:00:00Z<![CDATA[SAN DIEGO, April 22, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced closing of a Series C financing round, raising $142 million led by a $75 million equity investment from Novartis Pharma AG, and joined by several new investors including Aisling Capital Management, Pentwater Capital Management, Perceptive Advisors as well as additional undisclosed institutional investors. Current investors Malin Corporation plc., Longitude Capital, Vivo Capital and Boxer Capital, LLC also participated in the financing.]]>https://www.globenewswire.com/news-release/2019/02/13/1724586/0/en/Poseida-Therapeutics-Announces-Notice-of-Allowance-for-New-Patents-and-Registration-of-New-Trademarks.html?f=22&fvtc=4&fvtv=26810Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks2019-02-13T13:00:00Z<![CDATA[Key Patent Covers Manufacture of Therapeutic Products Containing a High Percentage of T Stem Cell Memory Cells Key Patent Covers Manufacture of Therapeutic Products Containing a High Percentage of T Stem Cell Memory Cells]]>https://www.globenewswire.com/news-release/2019/01/04/1680832/0/en/Poseida-Therapeutics-Appoints-Two-Independent-Directors-Adding-Leaders-for-Compensation-and-Governance-Functions.html?f=22&fvtc=4&fvtv=26810Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions2019-01-04T21:53:01Z<![CDATA[SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced the expansion of its board of directors with the appointment of Catherine J. Mackey, Ph.D., who will chair Poseida’s compensation committee, and Marcea Bland Lloyd, J.D., who will chair the nominating and governance committee.]]>https://www.globenewswire.com/news-release/2018/12/04/1661326/0/en/Poseida-Therapeutics-Provides-Update-on-Phase-1-Study-of-P-BCMA-101-CAR-T-Product-Candidate-at-the-2018-American-Society-of-Hematology-Annual-Meeting.html?f=22&fvtc=4&fvtv=26810Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting2018-12-04T02:15:00Z<![CDATA[P-BCMA-101 showed a 100% ORR with patients achieving rapid and deep responses with no CRS or neurotoxicity observed at the planned Phase 2 dose P-BCMA-101 showed a 100% ORR with patients achieving rapid and deep responses with no CRS or neurotoxicity observed at the planned Phase 2 dose]]>https://www.globenewswire.com/news-release/2018/11/29/1658904/0/en/Poseida-Therapeutics-to-Provide-Update-on-Phase-1-Study-of-P-BCMA-101-at-the-2018-American-Society-of-Hematology-Annual-Meeting.html?f=22&fvtc=4&fvtv=26810Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting2018-11-29T13:00:00Z<![CDATA[SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging proprietary next-generation, non-viral gene engineering technologies to create life-saving therapeutics, today announced that an update from the first five cohorts of an ongoing Phase 1 study of P-BCMA-101, Poseida’s lead autologous CAR-T therapeutic candidate for patients with relapsed/refractory multiple myeloma, will be presented at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego on December 3, 2018.]]>https://www.globenewswire.com/news-release/2018/11/05/1645024/0/en/Poseida-Therapeutics-Receives-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-from-FDA-for-P-BCMA-101.html?f=22&fvtc=4&fvtv=26810Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-1012018-11-05T13:00:00Z<![CDATA[SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging proprietary next-generation, non-viral gene engineering technologies to create life-saving therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to P-BCMA-101, Poseida’s lead CAR-T therapeutic candidate currently in a Phase 1 clinical trial for the treatment of patients with relapsed/refractory multiple myeloma. RMAT designation includes all of the benefits of the Fast Track and Breakthrough Therapy designation programs, including early interactions with the FDA.]]>https://www.globenewswire.com/news-release/2018/10/09/1618413/0/en/Poseida-Therapeutics-Appoints-Marcy-Graham-as-Vice-President-Corporate-Affairs.html?f=22&fvtc=4&fvtv=26810Poseida Therapeutics Appoints Marcy Graham as Vice President, Corporate Affairs2018-10-09T12:00:00Z<![CDATA[SAN DIEGO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced Marcy Graham has joined the company as vice president of corporate affairs. In this role, Ms. Graham will oversee investor relations, corporate communications and other functions within the organization.]]>https://www.globenewswire.com/news-release/2018/09/05/1565741/0/en/Poseida-Provides-Update-on-Phase-1-Study-of-P-BCMA-101-CAR-T-Stem-Cell-Memory-Product-in-Patients-with-Relapsed-Refractory-Multiple-Myeloma.html?f=22&fvtc=4&fvtv=26810Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma2018-09-05T13:15:00Z<![CDATA[Efficacy and safety continue to be a major advantage, with a very high response rate, no dose limiting toxicities and only a single incidence of suspected cytokine release syndrome]]>https://www.globenewswire.com/news-release/2018/08/29/1558065/0/en/Poseida-Therapeutics-Clinical-Update-of-BCMA-specific-CAR-T-Program-Selected-as-a-Late-Breaking-Presentation-at-the-4th-Annual-CAR-TCR-Summit-2018.html?f=22&fvtc=4&fvtv=26810Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018 2018-08-29T09:00:00Z<![CDATA[Three presentations focus on Poseida’s clinical and preclinical CAR-T programs Three presentations focus on Poseida’s clinical and preclinical CAR-T programs]]>